PAI-1, tPA, TFPI and HEECs in Uterine Hemostasis

Description

The purpose of the study is to learn more about the role of blood clotting factor proteins and cells in menstrual (period) bleeding. The investigators are hoping to identify differences in these proteins and cells in the menstrual blood of individuals with heavy periods compared to menstruating individuals who do not have heavy periods.

Conditions

Menstrual Bleeding, Heavy

Talk to us

Study Overview

On this page

Study Details

Study overview

The purpose of the study is to learn more about the role of blood clotting factor proteins and cells in menstrual (period) bleeding. The investigators are hoping to identify differences in these proteins and cells in the menstrual blood of individuals with heavy periods compared to menstruating individuals who do not have heavy periods.

The Role of Plasminogen Activator Inhibitor-1 (PAI-1), Tissue Plasminogen Activator (tPA), Tissue Factor Pathway Inhibitor (TFPI), and Endometrial Endothelial Cells in Uterine Hemostasis in Humans

PAI-1, tPA, TFPI and HEECs in Uterine Hemostasis

Condition
Menstrual Bleeding, Heavy
Intervention / Treatment

-

Contacts and Locations

Portland

OHSU, Portland, Oregon, United States, 97239

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

For general information about clinical research, read Learn About Studies.

Eligibility Criteria

  • * Regularly menstruating participants between 18-45 years of age
  • * Pregnancy within 3 months of enrollment
  • * Lactating at the time of enrollment
  • * Hormonal contraceptive use or use of the copper intrauterine device (IUD)
  • * Antifibrinolytic use
  • * Inherited or acquired bleeding disorder or anticoagulant use
  • * Known structural cause of HMB
  • * Inability to complete PBACs
  • * Unwilling to refrain from sexual intercourse for the two weeks prior to endometrial biopsy

Ages Eligible for Study

18 Years to 45 Years

Sexes Eligible for Study

FEMALE

Accepts Healthy Volunteers

Yes

Collaborators and Investigators

Oregon Health and Science University,

Study Record Dates

2026-07